DAXOR CORP (DXR) Stock Price & Overview

NASDAQ:DXR • US2394671034

Current stock price

11.3701 USD
-0.11 (-0.96%)
Last:

The current stock price of DXR is 11.3701 USD. Today DXR is down by -0.96%. In the past month the price decreased by -7.94%. In the past year, price increased by 36.5%.

DXR Key Statistics

52-Week Range7.1 - 14.7578
Current DXR stock price positioned within its 52-week range.
1-Month Range11.05 - 12.8999
Current DXR stock price positioned within its 1-month range.
Market Cap
66.288M
P/E
5.74
Fwd P/E
N/A
EPS (TTM)
1.98
Dividend Yield
N/A

DXR Stock Performance

Today
-0.96%
1 Week
+0.62%
1 Month
-7.94%
3 Months
-11.86%
Longer-term
6 Months -4.29%
1 Year +36.50%
2 Years +27.90%
3 Years +3.37%
5 Years -6.04%
10 Years +41.77%

DXR Stock Chart

DAXOR CORP / DXR Daily stock chart

DXR Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to DXR. When comparing the yearly performance of all stocks, DXR is one of the better performing stocks in the market, outperforming 74.05% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

DXR Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to DXR. DXR has an average financial health and profitability rating.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

DXR Earnings

Next Earnings DateN/A
Last Earnings DateMar 4, 2026
PeriodQ4 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %

DXR Forecast & Estimates

6 analysts have analysed DXR and the average price target is 23.8 USD. This implies a price increase of 109.32% is expected in the next year compared to the current price of 11.3701.

For the next year, analysts expect an EPS growth of -425% and a revenue growth 70% for DXR


Analysts
Analysts80
Price Target23.8 (109.32%)
EPS Next Y-425%
Revenue Next Year70%

DXR Groups

Sector & Classification

Index Membership

DXR Financial Highlights

Over the last trailing twelve months DXR reported a non-GAAP Earnings per Share(EPS) of 1.98. The EPS increased by 1068.54% compared to the year before.


Income Statements
Revenue(TTM)26.70K
Net Income(TTM)9.17M
Industry RankSector Rank
PM (TTM) 34343.82%
ROA 19.93%
ROE 19.98%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%329.99%
Sales Q2Q%-82.71%
EPS 1Y (TTM)1068.54%
Revenue 1Y (TTM)-77.71%

DXR Ownership

Ownership
Inst Owners1.45%
Shares5.83M
Float2.98M
Ins Owners5.08%
Short Float %0.12%
Short Ratio0.42

DXR Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABT ABBOTT LABORATORIES19.14187.722B
ISRG INTUITIVE SURGICAL INC47.3167.678B
SYK STRYKER CORP23.11128.879B
BSX BOSTON SCIENTIFIC CORP19.96102.581B
EW EDWARDS LIFESCIENCES CORP27.7347.515B
IDXX IDEXX LABORATORIES INC39.5645.688B
BDX BECTON DICKINSON AND CO11.7645.376B
RMD RESMED INC18.7833.629B
GEHC GE HEALTHCARE TECHNOLOGY13.9632.253B
DXCM DEXCOM INC26.0924.723B
ZBH ZIMMER BIOMET HOLDINGS INC1118.235B
HOLX HOLOGIC INC15.3116.77B
PODD INSULET CORP34.7515.477B

About DXR

Company Profile

DXR logo image Daxor Corp is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. The company specializes in blood volume measurement technology focused on blood volume testing innovation. The company markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. The company has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.

Company Info

IPO: 1983-07-25

DAXOR CORP

107 Meco Lane

Oak Ridge TENNESSEE 10118 US

CEO: Joseph Feldschuh

Employees: 0

DXR Company Website

DXR Investor Relations

Phone: 18654250555

DAXOR CORP / DXR FAQ

Can you describe the business of DAXOR CORP?

Daxor Corp is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. The company specializes in blood volume measurement technology focused on blood volume testing innovation. The company markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. The company has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.


Can you provide the latest stock price for DAXOR CORP?

The current stock price of DXR is 11.3701 USD. The price decreased by -0.96% in the last trading session.


What is the dividend status of DAXOR CORP?

DXR does not pay a dividend.


How is the ChartMill rating for DAXOR CORP?

DXR has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


What is the expected growth for DXR stock?

The Revenue of DAXOR CORP (DXR) is expected to grow by 70% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


What is DAXOR CORP worth?

DAXOR CORP (DXR) has a market capitalization of 66.29M USD. This makes DXR a Micro Cap stock.